Blog
RSS FeedPosted by Michael Wonder on 16 Dec 2025
Updated information about PHARMAC’s priority lists as at 15 December 2025
15 December 2025 - PHARMAC’s Prioritisation Update provides the latest information about applications for medicines, vaccines, and related products that ...
Posted by Michael Wonder on 14 Dec 2025
Highlights from the 8-11 December 2025 CHMP meeting
12 December 2025 - The EMA’s CHMP recommended seven medicines for approval at its December 2025 meeting. ...
Posted by Michael Wonder on 13 Dec 2025
Aflibercept 8 mg recommended for EU approval for third retinal indication
12 December 2025 - Positive opinion of the CHMP is based on the outcomes from the clinical Phase 3 trial QUASAR ...
Posted by Michael Wonder on 13 Dec 2025
PBAC weight loss drug decision imminent
12 December 2025 - Patients are spending as much as $5,000/year on private market GLP-1 therapies – an incoming PBAC recommendation ...
Posted by Michael Wonder on 13 Dec 2025
More efficacious dose of Wegovy recommended by the EMA can help people with obesity achieve an average of 20.7% weight loss
12 December 2025 - In the STEP UP programme, people with obesity taking Wegovy 7.2 mg lost an average of ...
Posted by Michael Wonder on 13 Dec 2025
Depemokimab receives positive CHMP opinion for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
12 December 2025 - Positive opinion based on four Phase 3 trials with statistically significant and clinically meaningful primary endpoints across ...
Posted by Michael Wonder on 13 Dec 2025
Nucala (mepolizumab) receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease
12 December 2025 - Positive opinion based on MATINEE Phase 3 trial showing significant reduction in COPD exacerbations versus placebo in ...
Posted by Michael Wonder on 13 Dec 2025
GSK’s RSV vaccine, Arexvy, receives positive CHMP opinion for all adults 18 years and older
12 December 2025 - GSK today announced that the EMA's CHMP has recommended expanding the indication of its adjuvanted recombinant respiratory ...
Posted by Michael Wonder on 13 Dec 2025
Cytokinetics announces positive CHMP opinion of Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy
12 December 2025 - Cytokinetics today announced that the CHMP of the EMA has adopted a positive opinion recommending marketing authorisation ...
Posted by Michael Wonder on 11 Dec 2025
ICER publishes evidence report on medication for smoking cessation
11 December 2025 - Cytisinicline is effective for smoking cessation; a 12 week course of cytisinicline would be cost effective ...
Posted by Michael Wonder on 11 Dec 2025
ICER releases draft evidence report on therapies for IgA nephropathy
10 December 2025 - Public comment period now open until 14 January 2026; Requests to make oral comment during public ...
Posted by Michael Wonder on 08 Dec 2025
EMA publishes agenda for 8-11 December 2025 CHMP meeting
8 December 2025 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 06 Dec 2025
New resource: understanding Canada’s drug approval and reimbursement pathway
3 December 2025 - Understanding how new oncology and non-oncology drugs move through Canada’s regulatory and drug access pathways can ...
Posted by Michael Wonder on 05 Dec 2025
Agenda for the December 2025 PBAC meeting
5 December 2025 - The agenda for the December 2025 PBAC meeting is now available. ...
Posted by Michael Wonder on 05 Dec 2025
Lecanemab in early Alzheimer's disease: previously unpublished data show no additional benefit
1 December 2025 - Based on previously unpublished data, the IQWiG concludes that lecanemab offers no proven advantage over the existing ...